The effect of epidermal growth factor (EGF) conjugated with low-molecular-weight protamine (LMWP) on wound healing of the skin

Biomaterials

Volumn 33, Issue 33, 2012, Pages 8579-8590

  Choi, Jin Kyu ^a   Jang, Ji Hye ^a   Jang, Won Hee ^a   Kim, Jaekwan ^a   Bae, Il Hong ^a   Bae, Joonho ^a   Park, Young Ho ^a   Kim, Beum Joon ^b   Lim, Kyung Min ^a   Park, Jin Woo ^a  

^a AmorePacific Corporation   (South Korea)

^b Chung Ang University   (South Korea)

Author keywords

Epidermal growth factor; Low molecular weight protamine; Protein transduction domain; Topical delivery; Transdermal delivery; Wound healing

Indexed keywords

EPIDERMAL GROWTH FACTORS; LOW MOLECULAR WEIGHT; PROTEIN TRANSDUCTION DOMAINS; TOPICAL DELIVERY; TRANSDERMAL DELIVERY; WOUND HEALING;

AMINO ACIDS; BIOACTIVITY; CELL PROLIFERATION; CHROMOSOMES;

PROTEINS;

ALPHA SMOOTH MUSCLE ACTIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR LOW MOLECULAR WEIGHT PROTAMINE CONJUGATE; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG PURIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN; SKIN PERMEABILITY; WOUND HEALING;

ANIMALS; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PROTAMINES; SKIN; WOUND HEALING;

EID: 84866165950     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.07.061     Document Type: Article

References (43)

1. Gurtner G.C., Werner S., Barrandon Y., Longaker M.T. Wound repair and regeneration. Nature 2008, 453:314-321.
2. Boateng J.S., Matthews K.H., Stevens H.N.E., Eccleston G.M. Wound healing dressings and drug delivery systems: a review. J Pharm Sci 2008, 97:2892-2923.
3. Dogan S., Demirer S., Kepenekci I., Erkek B., Kiziltay A., Hasirci N., et al. Epidermal growth factor-containing wound closure enhances wound healing in non-diabetic and diabetic rats. Int Wound J 2009, 6:107-115.
4. Barrientos S., Stojadinovic O., Golinko M.S., Brem H., Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen 2008, 16:585-601.
5. Judith R., Nithya M., Rose C., Mandal A.B. Application of a PDGF-containing novel gel for cutaneous wound healing. Life Sci 2010, 87:1-8.
6. Bao P., Kodra A., Tomic-Canic M., Golinko M.S., Ehrlich H.P., Brem H. The role of vascular endothelial growth factor in wound healing. J Surg Res 2009, 153:347-358.
7. Hardwicke J., Schmaljohann D., Boyce D., Thomas D. Epidermal growth factor therapy and wound healing -past, present and future perspectives. Surgeon 2008, 6:172-177.
8. Cohen S. The epidermal growth factor (EGF). Cancer 1983, 51:1787-1791.
9. Tolino M.A., Block E.R., Klarlund J.K. Brief treatment with heparin-binding EGF-like growth factor, but not with EGF, is sufficient to accelerate epithelial wound healing. Biochim Biophys Acta 2011, 1810:875-878.
10. Elloumi I., Kobayashi R., Funavashi H., Mie M., Kobatake E. Construction of epidermal growth factor fusion protein with cell adhesive activity. Biomaterials 2006, 27:3451-3458.
11. Imen EH, Nakamura M, Mie M, Kobatake E. Construction of multifunctional proteins for tissue engineering: epidermal growth factor with collagen binding and cell adhesive activities. J Biotechnol 139:19-25.
12. Berg A.V.D., Dowdy S.F. Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol 2011, 22:888-893.
13. Zorko M., Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 2005, 57:529-545.
14. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157:195-206.
15. Noguchi H., Matsushita M., Kobayashi N., Levy M.F., Matsumoto S. Recent advances in protein transduction technology. Cell Transplant 2010, 19:649-654.
16. Fonseca S.B., Pereira M.P., Kelley S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009, 61:953-964.
17. Torchilin V. Intracellular delivery of protein and peptide therapeutics. Drug Discov Today Technol 2008, 5:e95-e103.
18. Schmidt N., Mishra A., Lai G.H., Wong G.C.L. Arginine-rich cell penetrating peptides. FEBS Lett 2010, 584:1806-1813.
19. Park Y.J., Chang L.C., Liang J.F., Moon C., Chung C.P., Yang V.C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J 2005, 19:1555-1557.
20. Park Y.J., Liang J.F., Ko K.S., Kim S.W., Yang V.C. Low molecular weight protamine as an efficient and nontoxic gene carrier in vitro study. J Gene Med 2003, 5:700-711.
21. Choi Y.S., Lee J.Y., Suh J.S., Kwon Y.M., Lee S.J., Chung J.K., et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31:1429-1443.
22. Tsui B., Singh V.K., Liang J.F., Yang V.C. Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb Res 2001, 101:417-420.
23. Chang L.C., Wrobleski S., Wakefield T.W., Lee L.M., Yang V.C. Low molecular weight protamines as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci 2001, 3:24-31.
24. Huang Y., Park Y.S., Moon C., David A.E., Chung H.S., Yang V.C. Synthetic skin-permeable proteins enabling needleless immunizations. Angew Chem Int Ed Engl 2010, 49:2724-2727.
25. Liu M., Warn J.D., Fan Q., Smith P.G., Smith R.L. Relationships between nerves and myofibroblasts during cutaneous wound healing in the developing rat. Cell Tissue Res 1999, 297:423-433.
26. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005, 366:1736-1743.
27. Hou Y.W., Chan M.H., Hsu H.R., Liu B.R., Chen C.P., Chen H.H., et al. Transdermal delivery of proteins mediated non-covalently associated arginine-rich intracellular delivery peptides. Exp Dermatol 2007, 16:999-1006.
28. Shibagaki N., Okamoto T., Mitsui H., Inozuma T., Kanzaki M., Shimada S. Novel immunotherapeutic approaches to skin cancer treatments using protein transduction technology. J Dermatol Sci 2011, 61:153-161.
29. Lopes L.B., Brophy C.M., Furnish E., Flynn C.R., Sparks O., Komalavilas P., et al. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm Res 2005, 22:750-757.
30. Rothbard J.B., Garlington S., Lin Q., Kirschberg T., Kreider E., Mcgrane P.L., et al. Conjugation of arginine oligomers to cyclosporine A facilitates topical delivery and inhibition of inflammation. Nat Med 2000, 6:1253-1257.
31. Patlolla R.R., Desai P.R., Belay K., Singh M.S. Translocation of cell penetrating peptide engrafted nanoparticles across skin layers. Biomaterials 2010, 31:5598-5607.
32. Nakase I., Takeuchi T., Tanaka G., Futaki S. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides. Adv Drug Del Rev 2008, 60:598-607.
33. Kaplan I.M., Wadia J.S., Dowdy S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 2005, 102:247-253.
34. Thoren P.E., Persson D., Esbjorner E.K., Goksor M., Lincoln P., Norden B. Membrane binding and translocation of cell penetrating peptides. Biochemistry 2004, 43:3471-3489.
35. Ohtake K., Maeno H., Ueda H., Natsume H., Morimoto Y. Poly-L-arginine predominantly increase the paracellular permeability of hydrophilic macromolecules across rabbit nasal epithelium in vitro. Pharm Res 2003, 20:153-160.
36. Morita K., Myachi Y. Tight junctions in the skin. J Dermatol Sci 2003, 31:81-89.
37. Tuyet H.L., Quynh T.T.N., Minh H.V.H., Bich D.N.T., Dinh T.D., Tan D.L., et al. The efficacy and safety of epidermal growth factor in treatment of diabetic foot ulcers: the preliminary results. Int Wound J 2009, 6:159-166.
38. Ulubayram K., Cakar A.N., Korkusuz P., Ertan C., Hasirci N. EGF containing gelatin-based wound dressings. Biomaterials 2001, 22:1345-1356.
39. Hori K., Sotozono C., Hamuro J., Yamasaki K., Kimura Y., Ozeki M., et al. Controlled-release of epidermal growth factor from cationized gelatin hydrogel enhances corneal epithelial wound healing. J Control Release 2007, 118:169-176.
40. Choi J.S., Leong K.W., Yoo H.S. In vivo wound healing of diabetic ulcers using electrospun nanofibers immobilized with human epidermal growth factor (EGF). Biomaterials 2008, 29:587-596.
41. Hashimoto K., Higashiyama S., Asada H., Hashimura E., Kobayashi T., Sudo K., et al. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem 1994, 269:20060-20066.
42. Xu K.P., Li Y., Ljubimov A.V., Yu F.S.X. High glucose suppresses epidermal growth factor receptor/phosphatidylinositol 3-kinase/Akt signaling pathway and attenuates corneal epithelial wound healing. Diabetes 2009, 58:1077-1085.
43. Brown R.L., Breeden M.P., Greenhalgh D.G. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res 1994, 56:562-570.